Key Takeaways
- Record revenue, volume-led: Q3 FY26 revenue hit ₹233 crores (20% YoY), the 12th straight record quarter, driven by volume growth that outpaced revenue growth in a cost-plus model.
- CDMO is the engine: Generic Formulations CDMO grew 23% in Q3, fueled by customer expansion, injectable contributions, and Schedule-M tailwinds that are squeezing smaller players.
- Trade Generics hit a soft patch: Growth slowed to 7% in Q3 as competitive intensity rose and lumpy institutional orders weighed; management stays optimistic but won't quantify the path back.
- Plant 6 is the next catalyst: Mechanical completion is due by FY26-end, with commercialization targeted for H1 FY27; depreciation will hit in Q2 or Q3 FY27 under the WDV method.
- What to watch next quarter: Whether Trade Generics growth re-accelerates, the exact timing of Plant 6 commercialization and depreciation, and any sign that injectable utilization is approaching a level management is willing to discuss.
CDMO: The Core Growth Engine
- Broad-based volume growth: CDMO revenue grew 23% YoY in Q3 and 20% in 9M, with volume growth exceeding revenue growth as API prices stayed flat; the company operates a cost-plus model so volume is the true demand signal.
- Injectable ramp paying off: The injectable facility and Plant 2 extension, commissioned late last year, are contributing increasingly to CDMO growth as they scale.
- Schedule-M as a structural tailwind: Strong government enforcement has led to plant observations and closures among smaller players; compliance requires know-how, talent and systems, not just capital, and Windlas benefits from 70-80 multinational client audits per year that keep its standards high.
- Customer mix evolution: Growth is less about product mix shifts and more about how customers have changed their outsourcing patterns, which depends on Windlas' own capabilities rather than customer decisions on mix.
- Consolidation thesis intact: A fragmented CMO industry with 13,000+ players and rising regulatory pressure is bound to consolidate; management sees no reason for the industry to stay this fragmented.
Hitesh Windlass: "So schedule M compliance is not just about capital -- access to capital. It is about know-how, it is about talent and it is about systems. How do we maintain whatever we -- even if you achieve it once, then how do you stay compliant?"
Trade Generics: Growth Interrupted
- Quarterly slowdown: Trade Generics and Institutional grew only 7% in Q3 versus 18% in 9M, with management attributing the variation to lumpy institutional orders and rising competitive intensity as more players enter the space.
- Long-term thesis unchanged: Management remains very positive on the vertical's potential, citing macroeconomic factors, patient-level economics, and its AAA strategy (authentic, affordable, accessible); the focus stays on Tier 2 and Tier 3 towns and government programs like Jan Aushadhi.
- No growth rate commitment: When asked if Trade Generics can sustain 25-30% growth over 2-3 years, management declined to forecast, saying only that they will try their best to deliver good numbers; they referenced Leeford's journey as an analogy but gave no target.
- Industry data may undercount: Management questioned whether Indian pharma market volume growth of 1.6% fully captures government programs like Jan Aushadhi and Ayushman Bharat, implying the addressable market may be larger than reported.
Exports: Small Base, Binary Outcomes
- High growth off a low base: Exports grew 36% in Q3 and 29% in 9M, driven by increased penetration into RoW and semi-regulated markets including Southeast Asia, CIS and Africa; the company has zero sales to the US and zero to Europe.
- Binary and time-taking: Management cautioned that export results are often binary or take time to materialize, and declined to give qualitative color on work in progress until results come in, citing competitive reasons.
- Philippines approval: Post-approval from the Philippines was cited as a relevant milestone for the export growth outlook.
- Past efforts bearing fruit: Positive export results reflect groundwork laid 2-2.5 years ago, including securing South Africa audit clearance and starting one customer there; these are successes against many ongoing efforts.
Hitesh Windlass: "Avnish, so the -- as you correctly mentioned and I want to just reinforce, we have 0 sales to U.S. and 0 sales to Europe, right?"
Plant 6: The Next Capacity Catalyst
- Timeline: Mechanical completion is targeted by end of FY26, followed by quality systems validation and customer audits; commercialization is expected in H1 FY27, with partial contribution possible before full completion.
- India-focused: Plant 6 is not targeting the US or Europe; with more than 95% of sales to India, utilization will be focused on supporting all three domestic verticals.
- Depreciation impact: Capitalization is expected in H1 FY27, with depreciation starting in Q2 or Q3 FY27; initial depreciation will be higher because the company follows the WDV method, though the exact amount was not disclosed.
- Capacity philosophy: Capacity expansion follows business needs; the company has space to expand both oral solids and injectables when utilization warrants it, but management considers utilization rates too competitively sensitive to disclose.
Hitesh Windlass: "The capacity utilization number is a very competitive number, right? Because when you disclose that, your competitors understand how desperate -- and your customers also understand how desperate you are for business."
Margins & Financial Discipline
- Margin profile: EBITDA margin (ex-ESOP) stood at 13.6% for Q3 and 13.3% for 9M FY26; PAT margin was 9.6% for Q3 and 9% for 9M.
- ESOP cost treatment: The ESOP increase is not reflected in the overall EBITDA reduction; the company does not expect employee costs to decline despite ESOPs and continues to seek savings and operational efficiencies elsewhere.
- Cash position improving: Management declined to disclose the exact net cash position, citing unaudited limited-review financials, but confirmed improvement versus H1 and no negative change in the cash conversion cycle by December.
- Balanced risk appetite: The company likes to be cash-rich but is not risk-averse; it has taken debt for working capital and capex when needed, and aims to stay balanced, adaptive, flexible and opportunistic while maintaining discipline.
Strategy & Competitive Positioning
- Capability-led, not target-led: The 25-year journey is defined by capability building across dosage forms, geographies and product types; management believes that if execution skills are strong, there is no upper ceiling on growth and no strategic cliff.
- First-mover DNA: Windlas was the first Indian pharma CDMO to get a private equity investor, the first to go public, and the first to offer ESOP to employees; management takes pride in this willingness to lead.
- No guidance policy: The company has stopped sharing its internal long-term strategy externally and refrains from giving future guidance on revenue, bottom line or vertical-wise breakup; the stated intent is to "surprise pleasantly."
- Business development structure: The BD team is organized horizontally with dedicated teams for existing and new customers; senior management including the joint MD conducts aligned client visits.
Komal Gupta: "We would rather try to surprise you pleasantly. That is the intent and that is the effort is what I can tell you how we are able to execute it depends."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Plant 6 mechanical completion | Mechanical completion achieved | End of FY26 |
| Plant 6 commercialization | Ready for commercialization, partial contribution possible earlier | H1 FY27 |
| Plant 6 depreciation start | Capitalization in H1, depreciation begins under WDV method | Q2 or Q3 FY27 |
| Plant 6 market focus | Not targeting US or Europe; focused on India verticals | Ongoing |
| Export market focus | Zero sales to US, zero sales to Europe; focus on RoW and semi-regulated markets | Ongoing |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue from operations | ₹233 crores, +20% YoY |
| 9M FY26 revenue from operations | ₹666 crores, +19% YoY |
| EBITDA (reported) | ₹24 crores |
| EBITDA margin (reported) | 10.3% (per an analyst's math) |
| EBITDA (excl. ESOP) | ₹32 crores, 13.6% of revenue |
| PAT (reported) | ₹15 crores |
| PAT margin (reported) | 6.4% (per an analyst's math) |
| PAT (excl. ESOP) | ₹22 crores, 9.6% of revenue |
| 9M FY26 EPS | ₹24.02, +12% YoY |
| Generic Formulations CDMO vertical growth | +23% YoY |
| Trade Generics and Institutional verticals growth | +7% YoY |
| Exports vertical growth | +36% YoY |
| Indian pharma market growth | 11.8% YoY, volume growth of 1.6% |
| Plant 6 expected remaining capex | ~₹10 crores, total expected capex ₹50-60 crores |
| Quarterly depreciation run rate | ₹7.6-7.7 crores |
| Consecutive quarters of highest ever revenue | 12 quarters |